Cite
HARVARD Citation
Amuge, P. et al. (2022). Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet. 9 (9), pp. e638-e648. [Online].